Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union.

Company profile
Ticker
SGEN
Exchange
Website
CEO
Clay B. Siegall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
SEATTLE GENETICS INC /WA
SEC CIK
Corporate docs
Subsidiaries
Cascadian Therapeutics, LLC • East Coast Ventures, Inc. • Seagen Australia Pty Limited • Seagen Austria GmbH • Seagen B.V. • Seagen Canada Inc. • Seagen Denmark ApS • Seagen France SAS • Seagen Germany GmbH • Seagen International GmbH ...
IRS number
911874389
SGEN stock data
News

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
23 May 22
Seagen Reports Topline Results Of Pivotal Phase 2 Trial Of Co.'s TUKYSA In Combo With Trastuzumab In Metastatic Colorectal Cancer
23 May 22
'Police reports detailing Seagen CEO's arrest raise questions about biotech's response' -Article From STAT News
11 May 22
103 Biggest Movers From Yesterday
11 May 22
77 Stocks Moving In Tuesday's Mid-Day Session
10 May 22
Press releases
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
23 May 22
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
16 May 22
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
9 May 22
Seagen Reports First Quarter 2022 Financial Results
28 Apr 22
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
28 Apr 22
Analyst ratings and price targets
Current price
Average target
$154.50
Low target
$136.00
High target
$173.00
RBC Capital
Maintains
$136.00
Morgan Stanley
Maintains
$173.00
Calendar
28 Apr 22
24 May 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 261M | 261M | 261M | 261M | 261M | 261M |
Cash burn (monthly) | 54.61M | 9.39M | 45.08M | 58.32M | 72.27M | 49.21M |
Cash used (since last report) | 97.03M | 16.69M | 80.09M | 103.61M | 128.4M | 87.42M |
Cash remaining | 163.97M | 244.31M | 180.9M | 157.39M | 132.6M | 173.57M |
Runway (months of cash) | 3.0 | 26.0 | 4.0 | 2.7 | 1.8 | 3.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 22 | Charles R Romp | Common Stock | Sell | Dispose S | No | Yes | 134.2067 | 333 | 44.69K | 49,483 |
13 May 22 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,503 | 0 | 42,966,507 |
13 May 22 | Baker Bros. Advisors | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,503 | 0 | 4,088,765 |
13 May 22 | Baker Bros. Advisors | NQSO Common Stock | Grant | Acquire A | Yes | No | 135.63 | 3,676 | 498.58K | 3,676 |
13 May 22 | Simonian Nancy A | Common Stock | Grant | Acquire A | No | No | 0 | 1,503 | 0 | 54,003 |
13 May 22 | Simonian Nancy A | NQSO Common Stock | Grant | Acquire A | No | No | 135.63 | 3,676 | 498.58K | 3,676 |
13 May 22 | Welch Daniel G | Common Stock | Grant | Acquire A | No | No | 0 | 1,503 | 0 | 9,649 |
13 May 22 | Welch Daniel G | NQSO Common Stock | Grant | Acquire A | No | No | 135.63 | 3,676 | 498.58K | 3,676 |
13 May 22 | Love Ted W | Common Stock | Grant | Acquire A | No | No | 0 | 1,503 | 0 | 4,704 |
13 May 22 | Love Ted W | NQSO Common Stock | Grant | Acquire A | No | No | 135.63 | 3,676 | 498.58K | 3,676 |
Institutional ownership, Q1 2022
25.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.47B |
Total shares | 47.15M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 46.98M | $6.45B |
Partners Capital Investment | 164.35K | $23.68M |
Cibc World Markets | 5.32K | $766K |
North Star Asset Management | 2.75K | $396K |
Sofos Investments | 144 | $2K |
Financial report summary
?Competition
Pfizer • AMGEN • Cytrx • Kirin • Celgene • Spectrum Pharmaceuticals • Immunogen • Regeneron Pharmaceuticals • Biogen • AstrazenecaRisks
- Our success depends on our ability to effectively commercialize our products. If we and our collaborators are unable to effectively commercialize our products and to expand their utilization, our ability to generate significant revenue and our prospects for profitability will be adversely affected.
- Our success also depends on our ability to obtain regulatory approvals for our product candidates and for our current products in additional territories, as well as our ability to expand the labeled indications of use for our current products. Our inability to do so could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
- Even if regulatory approval is achieved, the launch of a new product or of an existing product in a new indication or territory is subject to a number of risks and uncertainties and may not be successful.
- Reports of adverse events or safety concerns involving our products or product candidates could delay or prevent us from obtaining or maintaining regulatory approvals or could negatively impact sales of our products or the prospects for our product candidates.
- Clinical trials and product development are expensive, time consuming and uncertain, may take longer than we expect and may not be successful. Our failure to effectively advance our development programs in a timely manner or at all could have a material adverse effect on our business, results of operations, financial condition and growth prospects.
- The successful commercialization of our products will depend, in part, on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.
- The successful commercialization of our products will also depend in part on the acceptance of our products by the medical community, patients and third-party payors.
- Any failures or setbacks in our ADC development program or our other platform technologies could negatively affect our business and financial position.
- We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
- Our products and any future approved products remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in penalties and significant additional expense and could negatively impact our and our collaborators’ ability to commercialize our current and any future approved products.
- Healthcare law and policy changes may negatively impact our business, including by decreasing the prices that we and our collaborators receive for our products.
- We are subject to various state, federal and international laws and regulations, including healthcare laws and regulations, that may impact our business and could subject us to significant fines and penalties or other negative consequences.
- Product liability and product recalls could harm our business, and we may not be able to obtain adequate insurance to protect us against product liability losses.
- Our operations involve hazardous materials and are subject to environmental, health and safety laws and regulations.
- Our collaborators and licensees may not perform as expected, which may negatively affect our ability to develop and commercialize our products and product candidates and/or generate revenues through technology licensing, and may otherwise negatively affect our business.
- We currently rely on third-party manufacturers and other third parties for production of our drug products, and our dependence on these third parties may impair the continued development and commercialization of our products and product candidates.
- We are dependent upon a small number of distributors for a significant portion of our net sales, and the loss of, or significant reduction or cancellation in sales to, any one of these distributors could adversely affect our revenues and increase our costs.
- We are dependent on third parties such as contract research organizations, medical institutions and clinical investigators to assist with the design, review, management and conduct of our clinical trials and other activities.
- If we are unable to enforce our intellectual property rights or if we fail to sustain and further procure additional intellectual property rights, we may not be able to successfully commercialize our products or any future products and competitors may be able to develop competing therapies.
- We may incur substantial costs and lose important rights or may not be able to continue to commercialize our products or to commercialize any of our product candidates that may be approved for commercial sale as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be required to obtain patent and other intellectual property rights from others.
- We and our collaborators rely on license agreements for certain aspects of our products and product candidates and technologies such as our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from continuing to develop and commercialize our products and product candidates.
- We have been and may in the future be subject to litigation, which could result in substantial expenses and damages and may divert management’s time and attention from our business.
- The evolving effects of the COVID-19 pandemic and associated global economic instability could have further adverse effects on our business, including our commercialization efforts, supply chain, regulatory activities, clinical development activities and other business operations.
- If we are unable to manage our growth, our business, results of operations, financial condition and growth prospects may be adversely affected.
- Risks associated with our expanding operations in countries outside the U.S. could materially adversely affect our business.
- We have engaged in, and may in the future engage in, strategic transactions that increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
- If we lose our key personnel or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer.
- If our information technology systems or data are or were compromised, we could experience interruptions to our operations, legal claims, liability, harm to our reputation, a loss of sales and other adverse impacts.
- Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
- We have a history of net losses. We expect to continue to incur net losses and may not achieve future sustained profitability for some time, if at all.
- We may need to raise additional capital that may not be available to us.
- The potential future impairment of intangible assets and goodwill may negatively affect our results of operations and financial position.
- Our stock price is volatile and our shares may suffer a decline in value.
- Substantial future sales or issuances of shares of our common stock or equity-related securities could cause the market price of our common stock to decline.
- Our existing stockholders have significant control of our management and affairs.
- Anti-takeover provisions could make it more difficult for a third party to acquire us.
- Our disclosures related to environmental, social and governance, or ESG, matters expose us to various risks, including risks to our reputation and stock price.
- Changes in tax laws or regulations may have a material adverse effect on our business, results of operations, financial condition or growth prospects.
- If our facilities are damaged or our research and development, manufacturing or other business processes are interrupted, our business could be seriously harmed.
- Legislative actions and new accounting pronouncements are likely to impact our future financial position or results of operations.
Management Discussion
- •Achieved 27% growth in net product sales for the quarter ended March 31, 2022 compared to the quarter ended March 31, 2021.
- •Entered into a collaboration with Sanofi to develop and potentially commercialize multiple novel ADCs. The agreement is an exclusive collaboration that will utilize Sanofi’s proprietary monoclonal antibody technology and our proprietary ADC technology for up to three cancer targets. Under the terms of the collaboration, Seagen and Sanofi will co-fund global development activities and share equally in any future profits. In the first quarter of 2022, the first, of up to three potential targets under the collaboration, was designated, for which Sanofi paid a license fee.
- •Announced that a jury found that Daiichi Sankyo willfully infringed our U.S. Patent No. 10,808,039 by selling in the U.S. its ENHERTU® product (trastuzumab deruxtecan; DS-8201). We were awarded damages of $41.8 million for past infringement of the patent. In addition, we intend to request a royalty on future sales of ENHERTU in the United States through November 5, 2024, as well as enhanced damages, attorney fees and costs.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
Absent, ABVD, accuracy, antitrust, Antonio, aspirational, asserted, attorney, bleomycin, book, branded, budgetary, camidanlumab, carcinoma, Circuit, commensurate, compound, conflict, conform, decelerate, deficient, disposal, elevated, ESG, exceed, exert, exploratory, forego, fulfill, Genitourinary, geopolitical, GU, HR, impost, IRC, Israel, jury, larger, leasehold, long, macroeconomic, military, Multidisciplinary, notably, online, partnership, penetrate, penetration, plant, pledge, pose, recommendation, regional, rehearing, relieve, remedial, remediation, reopened, repair, Russia, Russian, San, Sanofi, sequence, speaker, Squibb, suggest, surveillance, Symposium, tesirine, Ukraine, viability, vigorously, weather, willfully, withdrawn
Removed:
abandon, abroad, absenteeism, accept, accepting, accumulating, acting, adapt, advocacy, Affimed, affording, age, agreeing, allocation, Amgen, anesthesiologist, anticipation, applicant, approving, art, assimilating, assured, ASU, attracting, authorizing, award, ban, Bayer, Biogen, Biotech, BLA, Brexit, budget, build, call, certified, chance, charitable, cisplatin, clarifying, classification, climate, CMC, collectability, collecting, comfortable, Commerce, commit, communicate, comprise, confidence, conjugating, Corden, correctly, correspondingly, count, covering, custom, declined, dedicate, defend, departure, depended, destruction, detect, disclose, dispensed, distributing, dollar, doubtful, drying, economically, economy, Eisai, enhance, enjoined, equipped, error, Esteve, evolution, exacerbate, execute, expedient, explicit, explore, extrapolating, extraterritorial, FASB, fatigue, Fight, file, final, finance, financially, fluctuated, fluctuation, fluid, force, forecasted, foreseeable, formulation, frame, freely, French, frequent, fundamental, furlough, Gilead, govern, governed, heightening, HITECH, Hovione, identified, IDMC, ImmunoGen, inappropriate, incurrence, Infinity, ingredient, inherently, initiate, Innovation, instance, institution, insurer, invalidate, invite, jeopardize, Karyopharm, KGaA, lack, Lancet, learn, legality, Lilly, litigated, litigating, living, locate, LTIP, magnitude, managed, media, MedImmune, MEI, Mersana, Millipore, Modernization, morbidity, NCCN, needy, neutrophil, noncompliance, notified, notwithstanding, obligated, occurring, offered, official, opt, ORR, overseen, participate, patentability, PDUFA, performed, Pfizer, physical, pill, Plankstadt, poison, practical, predictive, prescriber, presence, prevailing, Prevention, prioritization, priority, producing, profitable, prolonged, promised, prone, proportional, prosecute, protective, protocol, published, Puma, purported, put, qualification, question, Quimica, rash, recession, recruit, recruiting, referred, regime, reliant, removing, renegotiate, replacement, replicated, representing, requesting, requisite, reserved, retaining, revoked, sample, Sapin, satisfactory, scheduling, screening, separate, shared, shut, shutdown, Sigma, Simplifying, sized, slowdown, specifically, spray, stability, statistical, Sterling, strain, strict, strong, structure, submitting, subsequent, suitable, superior, supplier, surrogate, Sutro, technical, temperature, Teva, threatening, tie, title, Topic, topline, train, transit, transition, transitional, transmit, traveling, unacceptable, unaware, unclear, uncover, underwriting, underwritten, undesirable, unemployment, unforeseen, user, validate, validated, validation, variance, viable, vote, wholesale, wholly, wider, withdraw, withdrawing, worsening, Xencor
Financial reports
Current reports
8-K
Other Events
23 May 22
8-K
Submission of Matters to a Vote of Security Holders
19 May 22
8-K
Departure of Directors or Certain Officers
15 May 22
8-K
Departure of Directors or Certain Officers
8 May 22
8-K
Seagen Reports First Quarter 2022 Financial Results
28 Apr 22
8-K
Amendments to Articles of Incorporation or Bylaws
15 Apr 22
8-K
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
8 Apr 22
8-K
Departure of Directors or Certain Officers
11 Mar 22
8-K
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
9 Feb 22
8-K
Other Events
23 Nov 21
Registration and prospectus
S-3ASR
Automatic shelf registration
29 Dec 20
S-8
Registration of securities for employees
31 Jul 20
424B5
Prospectus supplement for primary offering
24 Jul 19
424B5
Prospectus supplement for primary offering
23 Jul 19
S-8
Registration of securities for employees
27 Jun 19
424B7
Prospectus with selling stockholder info
26 Jul 18
S-8
Registration of securities for employees
26 Jul 18
SC TO-T/A
Third party tender offer statement (amended)
8 Mar 18
SC TO-T/A
Third party tender offer statement (amended)
15 Feb 18
SC TO-T
Third party tender offer statement
7 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
30 Mar 22
DEFA14A
Additional proxy soliciting materials
31 Mar 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
1 Apr 20
DEFA14A
Additional proxy soliciting materials
10 May 19
DEF 14A
Definitive proxy
4 Apr 19
Other
CT ORDER
Confidential treatment order
24 Aug 20
CT ORDER
Confidential treatment order
13 Apr 20
CT ORDER
Confidential treatment order
6 Feb 20
CT ORDER
Confidential treatment order
28 Jan 20
CT ORDER
Confidential treatment order
28 Jan 20
CT ORDER
Confidential treatment order
17 Dec 19
CT ORDER
Confidential treatment order
14 Nov 19
CT ORDER
Confidential treatment order
8 Nov 19
CT ORDER
Confidential treatment order
20 Jun 19
CT ORDER
Confidential treatment order
22 Mar 19
Ownership
4
Seagen / CHARLES R ROMP ownership change
18 May 22
4
Seagen / Alpna Seth ownership change
17 May 22
4
Seagen / DAVID W GRYSKA ownership change
17 May 22
4
Seagen / John A Orwin ownership change
17 May 22
4
Seagen / TED W LOVE ownership change
17 May 22
4
Seagen / Nancy A Simonian ownership change
17 May 22
4
Seagen / DANIEL G WELCH ownership change
17 May 22
4
Seagen / JULIAN BAKER ownership change
17 May 22
4
Seagen / CLAY B SIEGALL ownership change
13 May 22
4
Seagen / CLAY B SIEGALL ownership change
22 Apr 22
Patents
Utility
CD19 binding agents and uses thereof
17 May 22
This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.
Utility
Beta-glucuronide-linker Drug Conjugates
12 May 22
Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.
Utility
Combination therapy using a LIV1-ADC and a chemotherapeutic
10 May 22
The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
Utility
CD47 Antibodies and Uses Thereof for Treating Cancer
5 May 22
Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided.
Utility
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
3 May 22
The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
Transcripts
2022 Q1
Earnings call transcript
28 Apr 22
2021 Q4
Earnings call transcript
10 Feb 22
2021 Q3
Earnings call transcript
29 Oct 21
2021 Q2
Earnings call transcript
30 Jul 21
2021 Q1
Earnings call transcript
1 May 21
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
30 Oct 20
2020 Q2
Earnings call transcript
31 Jul 20
2020 Q1
Earnings call transcript
1 May 20
2019 Q4
Earnings call transcript
6 Feb 20
Reddit threads
Anybody else just buying MSFT?
15 May 22
Daily Discussion Thread - April 28th, 2022
28 Apr 22
Daily Discussion Thread - April 27th, 2022
27 Apr 22
Daily Discussion Thread - April 26th, 2022
26 Apr 22
Daily Discussion Thread - April 25th, 2022
25 Apr 22
Might be time to buy the NASDAQ dip
7 Mar 22
Morning Update for Thursday, 2/10/22
10 Feb 22
Daily Discussion Thread - February 9th, 2022
9 Feb 22
Daily Discussion Thread - February 8th, 2022
8 Feb 22
Daily Discussion Thread - February 7th, 2022
7 Feb 22